Bill Sellers

Bill Sellers is a core institute member of the Broad Institute of MIT and Harvard and serves as director of the institute's Cancer Program. He is also a Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School.  Bill spent his academic career at the intersection of cancer biology and genomics, investigating mechanisms of tumor development. He collaborated with Matthew Meyerson to initiate the Broad’s first major cancer genomic efforts, leading to the discovery of EGFR mutations in lung cancer and the oncogenic role of MITF in melanoma.

Previously, Sellers served as VP/Global Head of Oncology at Novartis Institutes of BioMedical Research, where he oversaw small molecule, antibody-based and cell therapy drug discovery efforts in oncology. In addition, he initiated and led the Cancer Cell Line Encyclopedia project in collaboration with the Broad Institute.

He earned his B.S. in biology from Georgetown University and his M.D. from University of Massachusetts Medical School. He completed his internship and residency in internal medicine at University of California San Francisco before completing a clinical oncology fellowship at Dana-Farber. He completed postdoctoral training in the labs of Dr. David Livingston and William G. Kaelin.